Hepatitis C immune globulin (human) for the prevention of viral recurrence after liver transplantation.

Abstract

Immunoglobulin therapy has been used extensively in the treatment of infectious diseases. Hepatitis B immunoglobulin (HBIg) reduces the onset of infection in post-percutaneous exposure to Hepatitis B virus (HBV) and in infants of hepatitis B surface antigen (HBsAg)-positive mothers; it also significantly reduces the risk of recurrent HBV infection in liver transplant recipients, thus increasing the survival rate of this population. Prior to 1990, when plasma donors were not screened for the hepatitis C virus (HCV) antibody, the prevalence of HCV viremia after a liver transplant was found to be lower in those patients receiving HBIg containing anti-HCV antibodies. Phase I trials with chimpanzees demonstrated the ability of hepatitis C immune globulin (human) to decrease hepatic inflammation and to neutralize the HCV antibody, but this effect was not sustained over time. Phase I/II human studies have currently been unable to replicate the animal studies, but further trials are planned.

• Authors: Lawrence U Liu, Thomas D Schiano
• Journal: Expert review of clinical immunology (Expert Rev Clin Immunol) Vol. 3 Issue 2 Pg. 125-30 (Mar 2007) ISSN: 1744-8409 [Electronic] England
• PMID: 20477101 (Publication Type: Journal Article)